<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757727</url>
  </required_header>
  <id_info>
    <org_study_id>21dermato01</org_study_id>
    <nct_id>NCT04757727</nct_id>
  </id_info>
  <brief_title>Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)</brief_title>
  <official_title>Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dystrophic epidermolysis bullosa is a rare genetic pathology resulting in fragility of the&#xD;
      skin and mucous membranes, causing bubbles and wounds following trauma. Scarring is&#xD;
      pathological with a tendency to retraction. The gynecological and in particular the&#xD;
      vulvovaginal mucous membranes can be affected but no description of any series is available&#xD;
      in the literature. Likewise, some of these patients have a sexual and obstetrical life,&#xD;
      despite sometimes-severe damage, but again no specific data is available. The investitigator&#xD;
      thus wish to carry out a non-interventional multicenter prospective descriptive study. Better&#xD;
      knowledge of gynecological semiology in patients with EBD will allow better adaptation of&#xD;
      gynecological follow-up, screening for STDs and gynecological cancers, as well as possible&#xD;
      specific complications. This study would eventually allow the draw up of recommendations for&#xD;
      our gynecologist / obstetrician colleagues.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Descriptve evaluation of the recruited population</measure>
    <time_frame>12 months</time_frame>
    <description>Adult women (&gt; 18 years old) with hereditary dystrophic epidermolysis bullosa (dominant or recessive) followed at the Nice University Hospital or at the St Louis Hospital of the APHP.&#xD;
Descriptve evaluation of the recruited population Description of the anatomical and gynecological functional impairment of adult women with dystrophic epidermolysis bullosa.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>EDB</arm_group_label>
    <description>Adult women (&gt; 18 years old) with hereditary dystrophic epidermolysis bullosa (dominant or recessive) followed at the Nice University Hospital or at the St Louis Hospital of the APHP</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decriptive study of EDB</intervention_name>
    <description>data on EDB will be register</description>
    <arm_group_label>EDB</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult women (&gt; 18 years old) with hereditary dystrophic epidermolysis bullosa (dominant or&#xD;
        recessive) followed at the Nice University Hospital or at the St Louis Hospital of the&#xD;
        APHP.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old or older&#xD;
&#xD;
          -  with hereditary dystrophic epidermolysis bullosa (dominant or recessive)&#xD;
&#xD;
          -  followed at the Nice University Hospital or at the St Louis Hospital of the APHP.&#xD;
&#xD;
          -  not opposed to participation after being informed of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  men&#xD;
&#xD;
          -  age &lt; 18years old&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Christine CHIAVERINI</last_name>
    <phone>+33492036107</phone>
    <email>chiaverini.c@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de NICE</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine CHIAVERINI</last_name>
      <phone>+33492036107</phone>
      <email>chiaverini.c@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas HUBICHE</last_name>
      <email>thomas.hubiche@ap-hp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no data sharing plan is schedule</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

